Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 222

1.

Pyogenic Spondylodiscitis: Risk Factors for Adverse Clinical Outcome in Routine Clinical Practice.

Widdrington JD, Emmerson I, Cullinan M, Narayanan M, Klejnow E, Watson A, Ong ELC, Schmid ML, Price DA, Schwab U, Duncan CJA.

Med Sci (Basel). 2018 Oct 30;6(4). pii: E96. doi: 10.3390/medsci6040096.

2.

Diagnostic utility of the Minnesota Multiphasic Personality Inventory-2 Restructured Form in the epilepsy monitoring unit: Considering sex differences.

Duncan CJ, Roberts NA, Kirlin KA, Parkhurst D, Burleson MH, Drazkowski JF, Sirven JI, Noe KH, Crepeau AZ, Hoerth MT, Locke DEC.

Epilepsy Behav. 2018 Nov;88:117-122. doi: 10.1016/j.yebeh.2018.08.033. Epub 2018 Sep 25.

PMID:
30261450
3.

Acute kidney injury (AKI) associated with intravenous aciclovir in adults: Incidence and risk factors in clinical practice.

Ryan L, Heed A, Foster J, Valappil M, Schmid ML, Duncan CJA.

Int J Infect Dis. 2018 Sep;74:97-99. doi: 10.1016/j.ijid.2018.07.002. Epub 2018 Jul 7.

4.

The unholy trinity of human herpesvirus 8-associated malignancy in a person living with HIV-1.

Duncan CJA, Charlton FG, Bower M, Price DA.

AIDS. 2018 Jan 28;32(3):404-406. doi: 10.1097/QAD.0000000000001719. No abstract available.

PMID:
29309348
5.

Early-onset autoimmune disease due to a heterozygous loss-of-function mutation in TNFAIP3 (A20).

Duncan CJA, Dinnigan E, Theobald R, Grainger A, Skelton AJ, Hussain R, Willet JDP, Swan DJ, Coxhead J, Thomas MF, Thomas J, Zamvar V, Slatter MA, Cant AJ, Engelhardt KR, Hambleton S.

Ann Rheum Dis. 2018 May;77(5):783-786. doi: 10.1136/annrheumdis-2016-210944. Epub 2017 Jun 28. No abstract available.

6.

Viral Vector Malaria Vaccines Induce High-Level T Cell and Antibody Responses in West African Children and Infants.

Bliss CM, Drammeh A, Bowyer G, Sanou GS, Jagne YJ, Ouedraogo O, Edwards NJ, Tarama C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Afolabi MO, Tiono AB, Yaro JB, Adetifa UJ, Hodgson SH, Anagnostou NA, Roberts R, Duncan CJ, Cortese R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampmann B, Imoukhuede EB, Sirima SB, Bojang K, Hill AV, Nébié I, Ewer KJ.

Mol Ther. 2017 Feb 1;25(2):547-559. doi: 10.1016/j.ymthe.2016.11.003.

7.

Safety and Immunogenicity of ChAd63 and MVA ME-TRAP in West African Children and Infants.

Afolabi MO, Tiono AB, Adetifa UJ, Yaro JB, Drammeh A, Nébié I, Bliss C, Hodgson SH, Anagnostou NA, Sanou GS, Jagne YJ, Ouedraogo O, Tamara C, Ouedraogo N, Ouedraogo M, Njie-Jobe J, Diarra A, Duncan CJ, Cortese R, Nicosia A, Roberts R, Viebig NK, Leroy O, Lawrie AM, Flanagan KL, Kampman B, Bejon P, Imoukhuede EB, Ewer KJ, Hill AV, Bojang K, Sirima SB.

Mol Ther. 2016 Aug;24(8):1470-7. doi: 10.1038/mt.2016.83. Epub 2016 Apr 25.

8.

Human IFNAR2 deficiency: Lessons for antiviral immunity.

Duncan CJ, Mohamad SM, Young DF, Skelton AJ, Leahy TR, Munday DC, Butler KM, Morfopoulou S, Brown JR, Hubank M, Connell J, Gavin PJ, McMahon C, Dempsey E, Lynch NE, Jacques TS, Valappil M, Cant AJ, Breuer J, Engelhardt KR, Randall RE, Hambleton S.

Sci Transl Med. 2015 Sep 30;7(307):307ra154. doi: 10.1126/scitranslmed.aac4227.

9.

Genetic differentiation in spite of high gene flow in the dominant rainforest tree of southeastern Australia, Nothofagus cunninghamii.

Duncan CJ, Worth JR, Jordan GJ, Jones RC, Vaillancourt RE.

Heredity (Edinb). 2016 Jan;116(1):99-106. doi: 10.1038/hdy.2015.77. Epub 2015 Sep 9.

10.

Varicella zoster virus immunity: A primer.

Duncan CJ, Hambleton S.

J Infect. 2015 Jun;71 Suppl 1:S47-53. doi: 10.1016/j.jinf.2015.04.015. Epub 2015 Apr 25. Review.

PMID:
25917799
11.

Host genetic factors in susceptibility to mycobacterial disease.

Duncan CJ, Hambleton S.

Clin Med (Lond). 2014 Dec;14 Suppl 6:s17-21. doi: 10.7861/clinmedicine.14-6-s17. Review.

PMID:
25468913
12.

Macrophage infection via selective capture of HIV-1-infected CD4+ T cells.

Baxter AE, Russell RA, Duncan CJ, Moore MD, Willberg CB, Pablos JL, Finzi A, Kaufmann DE, Ochsenbauer C, Kappes JC, Groot F, Sattentau QJ.

Cell Host Microbe. 2014 Dec 10;16(6):711-21. doi: 10.1016/j.chom.2014.10.010. Epub 2014 Nov 20.

13.

Futility of CD4+ monitoring in HIV-1 patients with CD4+ cell count above 350 cells/μl on suppressive antiretroviral therapy.

Duncan CJ, Schmid ML, Schwab U, Price DA, Ong E.

AIDS. 2014 Nov 13;28(17):2638-9. doi: 10.1097/QAD.0000000000000469. No abstract available.

PMID:
25418545
14.

Assessment of humoral immune responses to blood-stage malaria antigens following ChAd63-MVA immunization, controlled human malaria infection and natural exposure.

Biswas S, Choudhary P, Elias SC, Miura K, Milne KH, de Cassan SC, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Osier FH, Hodgson SH, Duncan CJ, O'Hara GA, Long CA, Hill AV, Draper SJ.

PLoS One. 2014 Sep 25;9(9):e107903. doi: 10.1371/journal.pone.0107903. eCollection 2014.

15.

Importance of antimicrobial stewardship to the English National Health Service.

Dixon J, Duncan CJ.

Infect Drug Resist. 2014 May 30;7:145-52. doi: 10.2147/IDR.S39185. eCollection 2014. Review.

16.

Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Kimani D, Jagne YJ, Cox M, Kimani E, Bliss CM, Gitau E, Ogwang C, Afolabi MO, Bowyer G, Collins KA, Edwards N, Hodgson SH, Duncan CJ, Spencer AJ, Knight MG, Drammeh A, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Soipei P, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Chilengi R, Bojang K, Flanagan KL, Hill AV, Urban BC, Ewer KJ.

Mol Ther. 2014 Nov;22(11):1992-2003. doi: 10.1038/mt.2014.109. Epub 2014 Jun 16.

17.

High-multiplicity HIV-1 infection and neutralizing antibody evasion mediated by the macrophage-T cell virological synapse.

Duncan CJ, Williams JP, Schiffner T, Gärtner K, Ochsenbauer C, Kappes J, Russell RA, Frater J, Sattentau QJ.

J Virol. 2014 Feb;88(4):2025-34. doi: 10.1128/JVI.03245-13. Epub 2013 Dec 4.

18.

Analysis of human B-cell responses following ChAd63-MVA MSP1 and AMA1 immunization and controlled malaria infection.

Elias SC, Choudhary P, de Cassan SC, Biswas S, Collins KA, Halstead FD, Bliss CM, Ewer KJ, Hodgson SH, Duncan CJ, Hill AV, Draper SJ.

Immunology. 2014 Apr;141(4):628-44. doi: 10.1111/imm.12226.

19.

Protective CD8+ T-cell immunity to human malaria induced by chimpanzee adenovirus-MVA immunisation.

Ewer KJ, O'Hara GA, Duncan CJ, Collins KA, Sheehy SH, Reyes-Sandoval A, Goodman AL, Edwards NJ, Elias SC, Halstead FD, Longley RJ, Rowland R, Poulton ID, Draper SJ, Blagborough AM, Berrie E, Moyle S, Williams N, Siani L, Folgori A, Colloca S, Sinden RE, Lawrie AM, Cortese R, Gilbert SC, Nicosia A, Hill AV.

Nat Commun. 2013;4:2836. doi: 10.1038/ncomms3836.

20.

Cell-to-cell spread of HIV-1 and evasion of neutralizing antibodies.

Schiffner T, Sattentau QJ, Duncan CJ.

Vaccine. 2013 Dec 2;31(49):5789-97. doi: 10.1016/j.vaccine.2013.10.020. Epub 2013 Oct 17. Review.

PMID:
24140477
21.

High multiplicity HIV-1 cell-to-cell transmission from macrophages to CD4+ T cells limits antiretroviral efficacy.

Duncan CJ, Russell RA, Sattentau QJ.

AIDS. 2013 Sep 10;27(14):2201-6. doi: 10.1097/QAD.0b013e3283632ec4.

22.

Immune focusing and enhanced neutralization induced by HIV-1 gp140 chemical cross-linking.

Schiffner T, Kong L, Duncan CJ, Back JW, Benschop JJ, Shen X, Huang PS, Stewart-Jones GB, DeStefano J, Seaman MS, Tomaras GD, Montefiori DC, Schief WR, Sattentau QJ.

J Virol. 2013 Sep;87(18):10163-72. doi: 10.1128/JVI.01161-13. Epub 2013 Jul 10.

23.

OPAT outcomes in endocarditis.

Duncan CJ, Barr DA, Seaton RA.

BMJ. 2013 Apr 24;346:f2484. doi: 10.1136/bmj.f2484. No abstract available.

PMID:
23615590
24.

Comparison of modeling methods to determine liver-to-blood inocula and parasite multiplication rates during controlled human malaria infection.

Douglas AD, Edwards NJ, Duncan CJ, Thompson FM, Sheehy SH, O'Hara GA, Anagnostou N, Walther M, Webster DP, Dunachie SJ, Porter DW, Andrews L, Gilbert SC, Draper SJ, Hill AV, Bejon P.

J Infect Dis. 2013 Jul 15;208(2):340-5. doi: 10.1093/infdis/jit156. Epub 2013 Apr 9.

25.

Safety and immunogenicity of heterologous prime-boost immunisation with Plasmodium falciparum malaria candidate vaccines, ChAd63 ME-TRAP and MVA ME-TRAP, in healthy Gambian and Kenyan adults.

Ogwang C, Afolabi M, Kimani D, Jagne YJ, Sheehy SH, Bliss CM, Duncan CJ, Collins KA, Garcia Knight MA, Kimani E, Anagnostou NA, Berrie E, Moyle S, Gilbert SC, Spencer AJ, Soipei P, Mueller J, Okebe J, Colloca S, Cortese R, Viebig NK, Roberts R, Gantlett K, Lawrie AM, Nicosia A, Imoukhuede EB, Bejon P, Urban BC, Flanagan KL, Ewer KJ, Chilengi R, Hill AV, Bojang K.

PLoS One. 2013;8(3):e57726. doi: 10.1371/journal.pone.0057726. Epub 2013 Mar 19.

26.

Risk factors for failure of outpatient parenteral antibiotic therapy (OPAT) in infective endocarditis.

Duncan CJ, Barr DA, Ho A, Sharp E, Semple L, Seaton RA.

J Antimicrob Chemother. 2013 Jul;68(7):1650-4. doi: 10.1093/jac/dkt046. Epub 2013 Mar 8.

27.

Assessment of immune interference, antagonism, and diversion following human immunization with biallelic blood-stage malaria viral-vectored vaccines and controlled malaria infection.

Elias SC, Collins KA, Halstead FD, Choudhary P, Bliss CM, Ewer KJ, Sheehy SH, Duncan CJ, Biswas S, Hill AV, Draper SJ.

J Immunol. 2013 Feb 1;190(3):1135-47. doi: 10.4049/jimmunol.1201455. Epub 2013 Jan 4.

28.

Effect of intermittent preventative therapy for secondary prevention of severe malarial anaemia.

Duncan CJ.

Lancet Infect Dis. 2012 Dec;12(12):906; author reply 906-7. doi: 10.1016/S1473-3099(12)70236-0. No abstract available.

PMID:
23174373
29.

ChAd63-MVA-vectored blood-stage malaria vaccines targeting MSP1 and AMA1: assessment of efficacy against mosquito bite challenge in humans.

Sheehy SH, Duncan CJ, Elias SC, Choudhary P, Biswas S, Halstead FD, Collins KA, Edwards NJ, Douglas AD, Anagnostou NA, Ewer KJ, Havelock T, Mahungu T, Bliss CM, Miura K, Poulton ID, Lillie PJ, Antrobus RD, Berrie E, Moyle S, Gantlett K, Colloca S, Cortese R, Long CA, Sinden RE, Gilbert SC, Lawrie AM, Doherty T, Faust SN, Nicosia A, Hill AV, Draper SJ.

Mol Ther. 2012 Dec;20(12):2355-68. doi: 10.1038/mt.2012.223. Epub 2012 Oct 23.

30.

Improving targeted screening for hepatitis C in the UK.

Duncan CJ, Stewart E, Fox R.

BMJ. 2012 Oct 3;345:e6525. doi: 10.1136/bmj.e6525. No abstract available.

PMID:
23034845
31.

Incidental diagnosis in healthy clinical trial subjects.

Duncan CJ, Rowland R, Lillie PJ, Meyer J, Sheehy SH, O'Hara GA, Hamill M, Donaldson H, Dinsmore L, Poulton ID, Gilbert SC, McShane H, Hill AV.

Clin Transl Sci. 2012 Aug;5(4):348-50. doi: 10.1111/j.1752-8062.2011.00393.x. Epub 2012 Mar 6.

32.

Comparison of clinical and parasitological data from controlled human malaria infection trials.

Roestenberg M, O'Hara GA, Duncan CJ, Epstein JE, Edwards NJ, Scholzen A, van der Ven AJ, Hermsen CC, Hill AV, Sauerwein RW.

PLoS One. 2012;7(6):e38434. doi: 10.1371/journal.pone.0038434. Epub 2012 Jun 11.

33.

A consultation on the optimization of controlled human malaria infection by mosquito bite for evaluation of candidate malaria vaccines.

Laurens MB, Duncan CJ, Epstein JE, Hill AV, Komisar JL, Lyke KE, Ockenhouse CF, Richie TL, Roestenberg M, Sauerwein RW, Spring MD, Talley AK, Moorthy VS; Consensus Group on Design of Clinical Trials of Controlled Human Malaria Infection.

Vaccine. 2012 Aug 3;30(36):5302-4. doi: 10.1016/j.vaccine.2012.04.088. Epub 2012 May 31.

PMID:
22659449
34.

The emerging threat of untreatable gonococcal infection.

Duncan S, Duncan CJ.

N Engl J Med. 2012 May 31;366(22):2136. doi: 10.1056/NEJMc1203138. No abstract available.

PMID:
22646648
35.

Tick bite and early Lyme borreliosis.

Duncan CJ, Carle G, Seaton RA.

BMJ. 2012 May 14;344:e3124. doi: 10.1136/bmj.e3124. No abstract available.

PMID:
22586232
36.

Distinguishing malaria and influenza: early clinical features in controlled human experimental infection studies.

Lillie PJ, Duncan CJ, Sheehy SH, Meyer J, O'Hara GA, Gilbert SC, Hill AV.

Travel Med Infect Dis. 2012 Jul;10(4):192-6. doi: 10.1016/j.tmaid.2012.03.008. Epub 2012 Apr 22.

37.

Outpatient parenteral antimicrobial therapy with ceftriaxone, a review.

Duncan CJ, Barr DA, Seaton RA.

Int J Clin Pharm. 2012 Jun;34(3):410-7. doi: 10.1007/s11096-012-9637-z. Epub 2012 Apr 17. Review.

PMID:
22527482
38.

Can growth inhibition assays (GIA) predict blood-stage malaria vaccine efficacy?

Duncan CJ, Hill AV, Ellis RD.

Hum Vaccin Immunother. 2012 Jun;8(6):706-14. doi: 10.4161/hv.19712. Epub 2012 Apr 20. Review.

39.

Controlled human blood stage malaria infection: current status and potential applications.

Duncan CJ, Draper SJ.

Am J Trop Med Hyg. 2012 Apr;86(4):561-5. doi: 10.4269/ajtmh.2012.11-0504. Review.

40.

Preliminary assessment of the efficacy of a T-cell-based influenza vaccine, MVA-NP+M1, in humans.

Lillie PJ, Berthoud TK, Powell TJ, Lambe T, Mullarkey C, Spencer AJ, Hamill M, Peng Y, Blais ME, Duncan CJ, Sheehy SH, Havelock T, Faust SN, Williams RL, Gilbert A, Oxford J, Dong T, Hill AV, Gilbert SC.

Clin Infect Dis. 2012 Jul;55(1):19-25. doi: 10.1093/cid/cis327. Epub 2012 Mar 22. Erratum in: Clin Infect Dis. 2019 Jun 18;69(1):195.

41.

Phase Ia clinical evaluation of the safety and immunogenicity of the Plasmodium falciparum blood-stage antigen AMA1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Biswas S, Collins KA, O'Hara GA, Halstead FD, Ewer KJ, Mahungu T, Spencer AJ, Miura K, Poulton ID, Dicks MD, Edwards NJ, Berrie E, Moyle S, Colloca S, Cortese R, Gantlett K, Long CA, Lawrie AM, Gilbert SC, Doherty T, Nicosia A, Hill AV, Draper SJ.

PLoS One. 2012;7(2):e31208. doi: 10.1371/journal.pone.0031208. Epub 2012 Feb 21.

42.

Clinical assessment of a recombinant simian adenovirus ChAd63: a potent new vaccine vector.

O'Hara GA, Duncan CJ, Ewer KJ, Collins KA, Elias SC, Halstead FD, Goodman AL, Edwards NJ, Reyes-Sandoval A, Bird P, Rowland R, Sheehy SH, Poulton ID, Hutchings C, Todryk S, Andrews L, Folgori A, Berrie E, Moyle S, Nicosia A, Colloca S, Cortese R, Siani L, Lawrie AM, Gilbert SC, Hill AV.

J Infect Dis. 2012 Mar 1;205(5):772-81. doi: 10.1093/infdis/jir850. Epub 2012 Jan 24.

43.

What is the efficacy of the RTS,S malaria vaccine?

Duncan CJ, Hill AV.

BMJ. 2011 Dec 13;343:d7728. doi: 10.1136/bmj.d7728. No abstract available.

44.

Viral determinants of HIV-1 macrophage tropism.

Duncan CJ, Sattentau QJ.

Viruses. 2011 Nov;3(11):2255-79. doi: 10.3390/v3112255. Epub 2011 Nov 15. Review.

45.

A decade of vaccinating allergic travellers: a clinical audit.

McCallum AD, Duncan CJ, MacDonald R, Jones ME.

Travel Med Infect Dis. 2011 Sep;9(5):231-7. doi: 10.1016/j.tmaid.2011.08.003. Epub 2011 Oct 13.

PMID:
21999910
46.

Vaccination of people with suspected egg allergy is safe and feasible.

Duncan CJ, McCallum AD, Macdonald R, Jones ME.

BMJ. 2011 Sep 13;343:d5780; author reply d5783. doi: 10.1136/bmj.d5780. No abstract available.

PMID:
21914744
47.

Phase Ia clinical evaluation of the Plasmodium falciparum blood-stage antigen MSP1 in ChAd63 and MVA vaccine vectors.

Sheehy SH, Duncan CJ, Elias SC, Collins KA, Ewer KJ, Spencer AJ, Williams AR, Halstead FD, Moretz SE, Miura K, Epp C, Dicks MD, Poulton ID, Lawrie AM, Berrie E, Moyle S, Long CA, Colloca S, Cortese R, Gilbert SC, Nicosia A, Hill AV, Draper SJ.

Mol Ther. 2011 Dec;19(12):2269-76. doi: 10.1038/mt.2011.176. Epub 2011 Aug 23.

48.

Impact on malaria parasite multiplication rates in infected volunteers of the protein-in-adjuvant vaccine AMA1-C1/Alhydrogel+CPG 7909.

Duncan CJ, Sheehy SH, Ewer KJ, Douglas AD, Collins KA, Halstead FD, Elias SC, Lillie PJ, Rausch K, Aebig J, Miura K, Edwards NJ, Poulton ID, Hunt-Cooke A, Porter DW, Thompson FM, Rowland R, Draper SJ, Gilbert SC, Fay MP, Long CA, Zhu D, Wu Y, Martin LB, Anderson CF, Lawrie AM, Hill AV, Ellis RD.

PLoS One. 2011;6(7):e22271. doi: 10.1371/journal.pone.0022271. Epub 2011 Jul 22.

49.

Ceftriaxone-related agranulocytosis during outpatient parenteral antibiotic therapy.

Duncan CJ, Evans TJ, Seaton RA.

J Antimicrob Chemother. 2010 Nov;65(11):2483-4. doi: 10.1093/jac/dkq339. Epub 2010 Sep 1. No abstract available.

PMID:
20810422
50.

Increased "absence" of telomeres may indicate Alzheimer's disease/dementia status in older individuals with Down syndrome.

Jenkins EC, Ye L, Gu H, Ni SA, Duncan CJ, Velinov M, Pang D, Krinsky-McHale SJ, Zigman WB, Schupf N, Silverman WP.

Neurosci Lett. 2008 Aug 8;440(3):340-3. doi: 10.1016/j.neulet.2008.05.098. Epub 2008 Jun 18.

Supplemental Content

Loading ...
Support Center